Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Citius Oncology announced the first international shipment of LYMPHIR to Europe, expanding patient access through Named Patient Programs outside the U.S. The company notes that access in Europe is currently limited to these programs as LYMPHIR does not yet have marketing authorization from the European Medicines Agency.
Key figures
- Drug Name
- LYMPHIR™ (denileukin diftitox-cxdl)
- Market size estimate
- $400 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.